^
    BIOMARKER:
    Chr del(17p)
    Chr del(17p)
    CLL
    zanubrutinib
    Sensitive
    :
    A2
    EHA 2021 - 4d
    Chr del(17p)
    CLL
    venetoclax
    Sensitive
    :
    A1
    EHA 2021 - 4d
    Chr del(17p)
    CLL
    ibrutinib
    Sensitive
    :
    A1
    EHA 2021 - 4d
    Chr del(17p)
    Multiple Myeloma
    Isa-KRd
    Sensitive
    :
    C2
    EHA 2021 - 4d
    Chr del(17p)
    Small Lymphocytic Lymphoma
    LOXO-305
    Sensitive
    :
    C3
    EHA 2021 - 4d
    Chr del(17p)
    CLL
    LOXO-305
    Sensitive
    :
    C3
    EHA 2021 - 4d
    Chr del(17p)
    CLL
    FCR
    Sensitive
    :
    C3
    EHA 2021 - 4d
    Chr del(17p)
    Multiple Myeloma
    thalidomide
    Resistant
    :
    C3
    EHA 2021 - 4d
    Chr del(17p)
    CLL
    venetoclax + obinutuzumab
    Sensitive
    :
    A1
    Chr del(17p)
    CLL
    rituximab + idelalisib
    Sensitive
    :
    A1
    Chr del(17p)
    CLL
    acalabrutinib
    Sensitive
    :
    A1
    Chr del(17p)
    CLL
    idelalisib + ofatumumab
    Sensitive
    :
    A1
    Chr del(17p)
    CLL
    ofatumumab
    Sensitive
    :
    A2
    Chr del(17p)
    CLL
    rituximab
    Sensitive
    :
    A2
    Chr del(17p)
    CLL
    venetoclax + rituximab
    Sensitive
    :
    A2
    Chr del(17p)
    Small Lymphocytic Lymphoma
    zanubrutinib
    Sensitive
    :
    A2
    Chr del(17p)
    Small Lymphocytic Lymphoma
    rituximab
    Sensitive
    :
    A2
    Chr del(17p)
    Small Lymphocytic Lymphoma
    ibrutinib
    Sensitive
    :
    A2
    Chr del(17p)
    CLL
    idelalisib
    Sensitive
    :
    A2
    Chr del(17p)
    Small Lymphocytic Lymphoma
    ofatumumab
    Sensitive
    :
    A2
    Chr del(17p)
    Small Lymphocytic Lymphoma
    idelalisib
    Sensitive
    :
    A2
    Chr del(17p)
    Small Lymphocytic Lymphoma
    venetoclax
    Sensitive
    :
    A2
    Chr del(17p)
    Small Lymphocytic Lymphoma
    rituximab + idelalisib
    Sensitive
    :
    A2
    Chr del(17p)
    Small Lymphocytic Lymphoma
    duvelisib
    Sensitive
    :
    A2
    Chr del(17p)
    Small Lymphocytic Lymphoma
    venetoclax + rituximab
    Sensitive
    :
    A2
    Chr del(17p)
    Small Lymphocytic Lymphoma
    obinutuzumab
    Sensitive
    :
    A2
    Chr del(17p)
    Small Lymphocytic Lymphoma
    alemtuzumab
    Sensitive
    :
    A2
    Chr del(17p)
    Small Lymphocytic Lymphoma
    rituximab + alemtuzumab
    Sensitive
    :
    A2
    Chr del(17p)
    Small Lymphocytic Lymphoma
    venetoclax + obinutuzumab
    Sensitive
    :
    A2
    Chr del(17p)
    Small Lymphocytic Lymphoma
    acalabrutinib
    Sensitive
    :
    A2
    Chr del(17p)
    Small Lymphocytic Lymphoma
    obinutuzumab + acalabrutinib
    Sensitive
    :
    A2
    Chr del(17p)
    CLL
    lenalidomide
    Sensitive
    :
    A2
    VERI is free for non-commercial use, no login needed.
    Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
    For commercial access, including additional premium features, please contact us.
    By using VERI, you are agreeing to our
    and
    Privacy Policy
    ACCEPT COOKIES